- Current report filing (8-K)
July 21 2010 - 4:30PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
DC 20549
FORM 8-K
CURRENT
REPORT PURSUANT
TO
SECTION 13 OR 15(D) OF THE
SECURITIES
EXCHANGE ACT OF 1934
Date of
report (Date of earliest event reported):
July 19,
2010
Interleukin
Genetics, Inc.
(Exact
Name of Registrant as Specified in Its Charter)
Delaware
(State or
Other Jurisdiction of Incorporation)
001-32715
|
|
94-3123681
|
(Commission
File Number)
|
|
(IRS
Employer Identification No.)
|
|
|
|
135
Beaver Street Waltham, MA
|
|
02452
|
(Address
of Principal Executive Offices)
|
|
(Zip
Code)
|
(781)
398-0700
(Registrant’s
Telephone Number, Including Area Code)
(Former
Name or Former Address, if Changed Since Last Report)
Check the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions (
see
General
Instruction A.2. below):
o
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
|
|
|
o
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
|
|
|
o
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act
(17 CFR 240.14d-2(b))
|
|
|
o
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act
(17 CFR 240.13e-4(c))
|
ITEM
8.01
Other
Events
Interleukin
Genetics, Inc. (the “Company”) has received a letter from the U.S. Food and Drug
Administration (the “FDA”) inquiring about the Company’s Inherent Health brand
of genetic tests and stating that these tests appear to meet the definition of a
“device” as such term is defined by the FDA. The Company does not believe that
its Inherent Health tests are devices that are subject to review by the FDA, and
it intends to provide information to the FDA to support its
position. There can be no assurance, however, that the FDA will agree
with the Company’s position that the Inherent Health genetic tests do not
require review by the FDA.
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
|
|
Interleukin
Genetics, Inc.
|
|
|
(Registrant)
|
|
|
|
Date:
July 21, 2010
|
|
/s/
ELIOT M. LURIER
|
|
|
Eliot
M. Lurier
|
|
|
Chief
Financial Officer
|
|
|
(Signature)
|
Interleukin Genetics (AMEX:ILI)
Historical Stock Chart
From Oct 2024 to Nov 2024
Interleukin Genetics (AMEX:ILI)
Historical Stock Chart
From Nov 2023 to Nov 2024